---
title: "Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules | NBIX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286813263.md"
description: "Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules | NBIX Stock News"
datetime: "2026-05-18T12:05:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286813263.md)
  - [en](https://longbridge.com/en/news/286813263.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286813263.md)
---

# Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules | NBIX Stock News

Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules | NBIX Stock News

### Related Stocks

- [NBIX.US](https://longbridge.com/en/quote/NBIX.US.md)

## Related News & Research

- [Neurocrine Biosciences (NBIX) Valuation Check As New INGREZZA Real World Data Draws Fresh Attention](https://longbridge.com/en/news/287134643.md)
- [Neurocrine’s New Tardive Dyskinesia Trial Adds Fresh Optionality for NBIX Investors](https://longbridge.com/en/news/286946226.md)
- [Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal](https://longbridge.com/en/news/286873474.md)
- [ZenaTech Advances Three ZenaDrone Defense Platforms Through Blue UAS Certification Pathway | ZENA Stock News](https://longbridge.com/en/news/286910480.md)
- [Zenas BioPharma Insider Bought Shares Worth $1,012,800, According to a Recent SEC Filing](https://longbridge.com/en/news/286872009.md)